Table 1.
Patient characteristics stratified by sarcopenia status.
| Total (N=185) | Sarcopenia (+) (N=93) | Sarcopenia (-) (N=92) | P-value | ||
|---|---|---|---|---|---|
| Age, year | 59 [51-69] | 62 [55-70] | 57 [47-67] | 0.027 | |
| Sex | Male | 120 (64.9) | 85 (91.4) | 35 (38.0) | <0.001 |
| BMI, kg/m2 | 21.2 [18.9-23.2] | 20.6 [18.2-22.0] | 22.0 [19.8-24.8] | <0.001 | |
| Underweight (<18.5) | 40 (21.6) | 25 (26.9) | 15 (16.3) | 0.117 | |
| SMI, cm2/m2 | 41.8 [36.0-47.4] | 40.7 [34.6-44.3] | 44.8 [37.7-53.3] | <0.001 | |
| Pathology | Adenoca, MD | 57 (30.8) | 33 (35.5) | 25 (27.2) | 0.591 |
| Adenoca, PD | 103 (55.7) | 50 (53.8) | 53 (57.6) | ||
| Signet ring cell | 22 (11.9) | 9 (9.7) | 13 (14.1) | ||
| Neuroendocrine | 3 (1.6) | 1 (1.1) | 2 (2.2) | ||
| Molecular category | MSI-H | 19 (10.3) | 6 (6.5) | 13 (14.1) | 0.209 |
| EBV (+) | 13 (7.0) | 8 (8.6) | 5 (5.4) | ||
| MSS/EBV (-) | 142 (76.8) | 75 (80.6) | 67 (72.8) | ||
| Unknown | 11 (5.9) | 4 (4.3) | 7 (7.6) | ||
| PD-L1 status (22C3 CPS) | ≥1% | 49 (26.5) | 24 (25.8) | 25 (27.2) | 0.756 |
| <1% | 46 (24.9) | 24 (25.8) | 22 (23.9) | ||
| Unknown | 90 (48.6) | 45 (48.4) | 45 (48.9) | ||
| Number of metastatic sites | 2 [1-3] | 2 [1-3] | 2 [1-3] | 0.467 | |
| Peritoneal carcinomatosis | 127 (68.6) | 70 (75.3) | 57 (62.0) | 0.073 | |
| Distant organ metastasis | 115 (62.2) | 52 (55.9) | 63 (68.5) | 0.107 | |
| Previous curative surgery | 62 (33.5) | 30 (32.3) | 32 (34.8) | 0.835 | |
| Previous radiation therapy | 37 (20.0) | 18 (19.4) | 19 (20.7) | 0.971 | |
| Total dose | 35.0 [25.0-36.0] | 36.0 [30.0-36.0] | 30.0 [22.0-36.0] | 0.330 | |
| Fractional dose | 3.0 [3.0- 4.0] | 3.0 [3.0- 3.0] | 3.5 [3.0- 7.5] | 0.061 | |
| Immune-checkpoint blockade | Nivolumab | 81 (43.8) | 48 (51.6) | 33 (35.9) | 0.044 |
| Pembrolizumab | 104 (56.2) | 45 (48.4) | 59 (64.1) | ||
| White blood cell count (x 103/μL) | 6.26 [4.86-8.80] | 7.40 [5.32-9.57] | 5.54 [4.46-7.50] | 0.001 | |
| ANC (x 103/μL) | 3.92 [2.72-5.92] | 4.68 [3.45-6.58] | 3.12 [2.46-5.12] | 0.001 | |
| ALC (x 103/μL) | 1.48 [1.09-1.91] | 1.48 [1.09-1.91] | 1.52 [1.08-1.93] | 0.925 | |
| NLR | 2.6 [1.7- 4.5] | 3.3 [2.0- 4.9] | 2.3 [1.4- 3.8] | 0.003 | |
| NLR≥3 | 81 (43.8) | 49 (52.7) | 32 (34.8) | 0.021 | |
| Albumin (g/dL) | 3.8 [3.3- 4.2] | 3.8 [3.3- 4.1] | 3.8 [3.4- 4.2] | 0.329 | |
| Albumin<3.5 g/dL | 51 (27.6) | 26 (28.0) | 25 (27.2) | 1.000 |
Values are presented as the number of patients (%) or medians [interquartile range] BMI, body mass index; SMI, skeletal muscle index; Adenoca, adenocarcinoma; MD, moderately differentiated; PD, poorly differentiated; MSS, microsatellite stable; EBV, Epstein-Barr virus; MSI-H, microsatellite instability-high; PD-L1, programmed death-ligand 1; CPS, combined positive score; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil-lymphocyte ratio.